Malaysia’s health ministry welcomes medical cannabis clinical studies

Last updated on August 3rd, 2022 at 12:31 pm

As there are currently no clinical trials being conducted on products containing cannabis extract for medical purposes, the Health Ministry in Malaysia welcomes applications to conduct clinical trials on these products. Deputy Health Minister Dr. Noor Azmi said on Thursday that such trials are not being carried out at this time, July 28th.

In response to a query from the Malaysian parliament, he stated that the Dangerous Drugs Act of 1952, the Poisons Act of 1952, and the Sale of Drugs Act of 1952 all make it possible for cannabis extract to be provided, imported, sold, and used for medical purposes, research, or clinical trials.

Also Read: The 10 Richest People in Malaysia

According to Dr. Azmi, businesses that are in possession of sufficient scientific evidence demonstrating the usefulness of products containing cannabis extract for medical purposes are eligible to make an application to the Drug Control Authority of Malaysia (DCA) in order to register those products.

According to the advertising, companies who have medicinal cannabis products that have been approved in other countries are eligible to submit an application in order to have their products registered and promoted in Malaysia.

These remarks were given in response to a query from Syed Saddiq Syed Abdul Rahman (Muda-Muar), who asked MoH to provide the most recent information regarding the legalization and use of medical cannabis in Malaysia.

“The MOH does not reject studies on the effectiveness of medical cannabis; it is time we follow the steps of 40 countries that have used it to treat diseases including cancer, depression, and epilepsy; we are ready to look at this,” he said in a statement.

According to Dr. Azmi, a proposal to separate the legal interpretations of cannabis, medical cannabis, and hemp will depend on the conclusions of the special committee that has been entrusted to research and establish the path of the industry’s development.

“Therefore the need to amend the Dangerous Drugs Act 1952 in connection with the control of cannabis and hemp, including creating separate interpretations for cannabis and hemp, depends on the Cabinet’s decision after reviewing the committee’s findings, taking into account the legal, socio-cultural, health, economy, Syariah law aspects and so on,” he further added to his statement.